Jitsubo CO., LTD. announced  the signing of an exclusive manufacturing license agreement with Novo Nordisk A/S（2880 Bagsvaerd, Denmark, hereinafter “Novo Nordisk”）for Novo Nordisk to use and have manufacturing rights to Jitsubo’s proprietary peptide manufacturing technology, Molecular Hiving^TM, for synthesis of peptides in the field of obesity, diabetes, and the related therapeutic areas.

News Release PDF

CPHI Japan2023

We are pleased to announce that we will be exhibiting together with SPERA PHARMA,  Inc. and SPERA NEXUS, Inc. of the Astena Holdings.

◆Date : 19th to 21th, April 2023

◆Place : Tokyo Big Sight Exhibition Center, Tokyo, Japan

◆Booth :5H-12

For further details, please visit website.

https://www.cphi.com/japan/

See the details (PDF)

On July 26, 2021, Jitsubo received ISO27001 certification, an international standard for Information Security Management Systems (ISMS) that covers the development and operation of information assets and internal systems.

With this certification, we will establish a high-level information management system that fully meets global standards, and we will continue to maintain and improve our information security management to provide services that earn the trust of our customers.

See the Details (PDF)

IWAKI & CO., LTD., a leading specialized pharmaceutical trading company, has announced today its acquisition of Jitsubo CO., LTD., a pharmaceutical venture with unique liquid phase peptide manufacturing technology, Molecular Hiving™, through its 100% subsidiary, SPERA PHARMA, Inc. a CMC R&D contract company. With this transaction, Jitsubo has become 100% subsidiary of SPERA PHARMA.

More Details(PDF)

Bubendorf/Basel, Switzerland and Yokohama, Japan, May 8, 2020 – Bachem (SIX: BANB) and Jitsubo CO., LTD. announce today that they signed an exclusive Licensing Agreement for Jitsubo’s Molecular Hiving™ technology. Under the License agreement, Jitsubo will develop selected manufacturing processes using their Molecular Hiving™ technology and transfer these processes to Bachem. Bachem will further optimize, scale up and produce for commercial applications. In return, Jitsubo will receive development fees and royalties.

News Release PDF

Publications